News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Supremes to Review Amgen (AMGN) Stock Fraud Case


6/12/2012 6:57:49 AM

The U.S. Supreme Court will decide whether investors must prove that misinformation from Amgen (AMGN) (AMGN) Inc. propped up its stock price before they can pursue a class-action stock-fraud suit against the world’s largest biotechnology company. The justices today agreed to review an appeal by Amgen in a case alleging the company and its executives misled investors for more than three years about safety questions involving its Aranesp and Epogen anemia drugs. Amgen says a federal appeals court ruling makes it too easy to mount class-action lawsuits representing thousands of people, pressuring companies to pay settlements for even frivolous allegations rather than risk huge damages in a trial. Amgen’s appeal is backed by the U.S. Chamber of Commerce and the pharmaceutical industry’s trade group.

Read at BusinessWeek
Read at Fox News
Read at News Release
Read at Wall Street Journal
Read at Pharmalot


comments powered by Disqus
Amgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES